FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3086702451> ?p ?o ?g. }

• W3086702451 endingPage "2408" @default.
• W3086702451 startingPage "2387" @default.
• W3086702451 abstract "The humanized Delta-like 4 (DLL4) monoclonal antibody H3L2 with a quite high affinity for hrDLL4 inhibits the DLL4-mediated human umbilical vein endothelial cell (HUVEC) phenotype, inducing dysfunctional angiogenesis and tumour cell apoptosis, which effectively arrests breast cancer cell growth in vivo. To develop a more effective therapy, an engineered cysteine residue at alanine 121 (Kabat numbering) on each H3L2 heavy chain or at valine 207 (Kabat numbering) on each H3L2 light chain was established by site-directed mutagenesis. Three engineered antibodies, THL4, TH2 and TL2, were identified, and the specific-site antibody-drug conjugates (ADCs) THL4-mpeoDM1 (named HLmD4), TH2-mpeoDM1 (named HmD2), TL2-mpeoDM1 (named LmD2) and THL4-vcMMAE (named HLvM4), were produced, which exhibit much more potent antitumour activity than the naked antibody. The engineered ADCs can be directed against DLL4 and effectively internalized, followed by the release of small molecule cytotoxic agents, e.g., DM1 or MMAE, into the cytosol, which inhibit the synthesis of microtubules and induce G2/M phase growth arrest and cell death through the induction of apoptosis. ADC-conjugated DM1 was highly potent against DLL4-expressing cells in vitro. We systematically compared the in vitro potency and the in vivo preclinical efficacy and safety profiles of the heterogeneous conventional ADC, H3L2-mpeoDM1 (named JmD4) with that of the homogeneous engineered conjugate HLmD4. The engineered anti-DLL4 ADCs, particularly HLmD4, showed more potent antitumour activity than Docetaxel and superior safety compared with JmD4 in two xenograft tumour models. Our findings indicate that engineered ADCs have promising potential as effective preclinical therapies for cancers." @default.
• W3086702451 created "2020-09-21" @default.
• W3086702451 creator A5012297714 @default.
• W3086702451 creator A5015102287 @default.
• W3086702451 creator A5021291753 @default.
• W3086702451 creator A5028073296 @default.
• W3086702451 creator A5059972066 @default.
• W3086702451 creator A5065825259 @default.
• W3086702451 creator A5067544396 @default.
• W3086702451 creator A5082406647 @default.
• W3086702451 date "2020-01-01" @default.
• W3086702451 modified "2023-09-27" @default.
• W3086702451 title "Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models." @default.
• W3086702451 cites W1810291737 @default.
• W3086702451 cites W1969669189 @default.
• W3086702451 cites W1978925562 @default.
• W3086702451 cites W1992175481 @default.
• W3086702451 cites W1995239905 @default.
• W3086702451 cites W2014016903 @default.
• W3086702451 cites W2034609970 @default.
• W3086702451 cites W2051319925 @default.
• W3086702451 cites W2094477446 @default.
• W3086702451 cites W2116150122 @default.
• W3086702451 cites W2117748018 @default.
• W3086702451 cites W2120843102 @default.
• W3086702451 cites W2123366765 @default.
• W3086702451 cites W2131232783 @default.
• W3086702451 cites W2137170183 @default.
• W3086702451 cites W2140836243 @default.
• W3086702451 cites W2156506990 @default.
• W3086702451 cites W2159967578 @default.
• W3086702451 cites W2170426247 @default.
• W3086702451 cites W2170785598 @default.
• W3086702451 cites W2198545326 @default.
• W3086702451 cites W2248346391 @default.
• W3086702451 cites W2302699227 @default.
• W3086702451 cites W2423432333 @default.
• W3086702451 cites W2595120106 @default.
• W3086702451 cites W2735285257 @default.
• W3086702451 cites W2756477598 @default.
• W3086702451 cites W2760931533 @default.
• W3086702451 cites W2773876441 @default.
• W3086702451 cites W2784219914 @default.
• W3086702451 cites W2798249412 @default.
• W3086702451 cites W2808724999 @default.
• W3086702451 cites W2884685998 @default.
• W3086702451 cites W2898183660 @default.
• W3086702451 cites W2922085672 @default.
• W3086702451 cites W2948531293 @default.
• W3086702451 cites W2965572865 @default.
• W3086702451 cites W8834295 @default.
• W3086702451 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7471348" @default.
• W3086702451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32905508" @default.
• W3086702451 hasPublicationYear "2020" @default.
• W3086702451 type Work @default.
• W3086702451 sameAs 3086702451 @default.
• W3086702451 citedByCount "1" @default.
• W3086702451 countsByYear W30867024512022 @default.
• W3086702451 crossrefType "journal-article" @default.
• W3086702451 hasAuthorship W3086702451A5012297714 @default.
• W3086702451 hasAuthorship W3086702451A5015102287 @default.
• W3086702451 hasAuthorship W3086702451A5021291753 @default.
• W3086702451 hasAuthorship W3086702451A5028073296 @default.
• W3086702451 hasAuthorship W3086702451A5059972066 @default.
• W3086702451 hasAuthorship W3086702451A5065825259 @default.
• W3086702451 hasAuthorship W3086702451A5067544396 @default.
• W3086702451 hasAuthorship W3086702451A5082406647 @default.
• W3086702451 hasConcept C121608353 @default.
• W3086702451 hasConcept C150903083 @default.
• W3086702451 hasConcept C159654299 @default.
• W3086702451 hasConcept C185592680 @default.
• W3086702451 hasConcept C202751555 @default.
• W3086702451 hasConcept C203014093 @default.
• W3086702451 hasConcept C207001950 @default.
• W3086702451 hasConcept C2780394083 @default.
• W3086702451 hasConcept C502942594 @default.
• W3086702451 hasConcept C542903549 @default.
• W3086702451 hasConcept C54355233 @default.
• W3086702451 hasConcept C55493867 @default.
• W3086702451 hasConcept C86803240 @default.
• W3086702451 hasConcept C96232424 @default.
• W3086702451 hasConcept C98274493 @default.
• W3086702451 hasConceptScore W3086702451C121608353 @default.
• W3086702451 hasConceptScore W3086702451C150903083 @default.
• W3086702451 hasConceptScore W3086702451C159654299 @default.
• W3086702451 hasConceptScore W3086702451C185592680 @default.
• W3086702451 hasConceptScore W3086702451C202751555 @default.
• W3086702451 hasConceptScore W3086702451C203014093 @default.
• W3086702451 hasConceptScore W3086702451C207001950 @default.
• W3086702451 hasConceptScore W3086702451C2780394083 @default.
• W3086702451 hasConceptScore W3086702451C502942594 @default.
• W3086702451 hasConceptScore W3086702451C542903549 @default.
• W3086702451 hasConceptScore W3086702451C54355233 @default.
• W3086702451 hasConceptScore W3086702451C55493867 @default.
• W3086702451 hasConceptScore W3086702451C86803240 @default.
• W3086702451 hasConceptScore W3086702451C96232424 @default.
• W3086702451 hasConceptScore W3086702451C98274493 @default.
• W3086702451 hasIssue "8" @default.

• next